Volume 2 Supplement 1

Second International Symposium on the Molecular Biology of Breast Cancer

Open Access

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer

  • TI Andersen1, 3,
  • E Skovlund4,
  • IK Bukholm3,
  • U Jacobsen2,
  • R Kåresen2,
  • B Erikstein4,
  • J Nesland5 and
  • A-L Børresen-Dale3
Breast Cancer Research20002(Suppl 1):P3.07


Published: 12 March 2000

Full text

Activation of the HER-2 proto-oncogene and inactivation of the TP53 tumour-suppressor gene belong to the most common genetic changes in human breast carcinomas. Both appear to be of prognostic significance, at least in patients with node-positive disease. The relevance of these changes in node-negative disease, however, still remains uncertain. Moreover, the relationship between HER-2 and TP53 status remains to be fully clarified.

HER-2 and TP53 status were determined in 261 breast carcinomas collected from Norwegian breast cancer patients diagnosed between 1984 and 1994. HER-2 status was determined using immunohistochemistry. A subset of the tumours was also examined with regard to gene amplification using the Southern blot technique. A significant association was found between the presence of gene amplification and positive HER-2 immunostaining in the tumour. The tumours were also examined for TP53 alterations using CDGE (constant denaturant gel electrophoresis) and immunohistochemistry. A significant association was found between the presence of HER-2 activation and TP53 inactivation in the tumour. Survival analyses will be presented.

Authors’ Affiliations

Departments of Oncology
Surgery, Ullevål University Hospital
Departments of Genetics
Pathology, The Norwegian Radium Hospital


© Current Science Ltd 2000